Anti-TROP2 Antibody (Sacituzumab)
Catalog No.
F1369
Anti-TROP2 Antibody (Sacituzumab)
Featured Products
Sacituzumab is a humanized IgG1 monoclonal antibody targeting trophoblast cell surface antigen 2 (TROP2). Sacituzumab alone lacks anti-tumor effects, does not inhibit the function of TROP-2 during tumor metastasis, and can bind to the linear epitope of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugate (ADC) drugs. The TROP-2-targeting sacituzumab (sacituzumab govitecan) (HY -132254) antibody-drug conjugate has been approved for use in the field of triple-negative breast cancer.
Quality Control & DataSheet
- View current batch:
-
Purity > 95% by SDS-PAGE and SEC-HPLC analyses.
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
- Datasheet
145.52 kDa
Dry ice
1796566-95-4
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
HRS7
100 mM Pro 20 mM Arg pH 5.0. No preservative!
P09758
Human, Mouse
Unconjugated
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
Immobilized human TROP2 His at 2 ug/mL can bind Anti-TROP2 Antibody (Sacituzumab)
TROP2
Please avoid freeze-thaw cycles.